Insider Transactions in Q4 2020 at Repare Therapeutics Inc. (RPTX)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
19,696
-10.03%
|
$669,664
$34.31 P/Share
|
|
Dec 28
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
15,048
-8.86%
|
$511,632
$34.42 P/Share
|
|
Dec 28
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
48
+0.06%
|
$96
$2.06 P/Share
|
|
Dec 24
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
432
-0.5%
|
$14,256
$33.14 P/Share
|
|
Dec 24
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
432
+0.5%
|
$864
$2.06 P/Share
|
|
Dec 23
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
16,235
-8.26%
|
$535,755
$33.87 P/Share
|
|
Dec 23
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
16,235
+5.23%
|
$32,470
$2.04 P/Share
|
|
Dec 22
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
41,312
-16.53%
|
$1,363,296
$33.68 P/Share
|
|
Dec 22
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
41,312
+15.15%
|
$41,312
$1.85 P/Share
|
|
Dec 21
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
40,000
-31.94%
|
$1,320,000
$33.08 P/Share
|
|
Dec 21
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+24.21%
|
$80,000
$2.42 P/Share
|
|
Dec 18
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
8,321
-4.46%
|
$282,914
$34.84 P/Share
|
|
Dec 18
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,321
+8.17%
|
$16,642
$2.06 P/Share
|
|
Dec 16
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
8,956
-4.8%
|
$313,460
$35.59 P/Share
|
|
Dec 16
2020
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,956
+4.55%
|
$8,956
$1.64 P/Share
|
|
Dec 15
2020
|
Versant Ventures V, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
325,000
-10.12%
|
-
|
|
Dec 15
2020
|
Davis Jerel Director |
SELL
Other acquisition or disposition
|
Indirect |
325,000
-10.12%
|
-
|
|
Dec 15
2020
|
Versant Vantage I, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
325,000
-10.12%
|
-
|